Evening With the Experts: Clinical Decision-Making for Patients With HR+ HER2- Early Breast Cancer

Join us for a live webinar to learn more about assessing the risk of recurrence and selecting appropriate CDK4/6 inhibitor–based therapy for patients with HR+/HER2- early breast cancer and managing adverse events associated with current and emerging therapies. This event will offer the attendees the opportunity to have their questions answered by the expert panel.

Not an official event of the 2021 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO, CancerLinQ, or Conquer Cancer.

To Register: On the Event Dates page click a date/time, click blue Register button in upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.

Agenda

  • Welcome and introduction
  • Use of biomarkers and genomic classifiers to assess risk of recurrence
  • Adjuvant therapy with CDK4/6 inhibitors ± endocrine therapy
  • Neoadjuvant therapy considerations with CDK4/6 inhibitors
  • Future considerations on the horizon for HR+/HER2- EBC
  • Audience question and answer session

Events

Date / Time
Event Details

Faculty

Faculty
Sara Hurvitz, MD

Associate Professor of Medicine
Director,
Breast Oncology Program
Division of Hematology-Oncology
Department of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

Faculty
Joyce O'Shaughnessy, MD

Celebrating Women Chair in Breast Cancer Research
Director,
Breast Cancer Research Program
Baylor University Medical Center
Texas Oncology
US Oncology Network
Dallas, Texas

Faculty
Sara Tolaney, MD, MPH

Assistant Professor of Medicine
Harvard Medical School
Associate Director, Susan F Smith Center for Women's Cancers
Dana-Farber/Brigham and Women's Cancer Center
Boston, MA, USA

Goal Statement
The goal of this activity is to improve the knowledge, confidence, competence, and performance of learners in selecting individualized treatment for patients with HR+/HER2- early-stage breast cancer.

Target Audience
This program is intended for physicians and other healthcare providers who care for patients with breast cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Appraise current/emerging published data and consensus-based guidelines to inform the use of biomarkers and genomic classifiers to assess risk of recurrence
  • Individualize the selection of systemic therapy for appropriate patients with HR+/HER2- EBC to include CDK4/6 inhibitors with or without endocrine therapy
  • Develop strategies to anticipate, monitor, and manage adverse events with current and emerging therapies for HR+/HER2- EBC to support quality of life and continuation of care
  • Identify patients with HR+/HER2- EBC eligible for enrollment on ongoing clinical studies investigating novel therapies

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.